HLA-Cw*18 Product Insert Page 1 of 8 101.629-06u – without *Taq* polymerase

,. ,

Lot No.: **70E** Lot-specific information

Olerup SSP® HLA-Cw*18

Product number: 101.629-06u – without *Taq* polymerase

Lot number: 70E

Expiry date: 2010-July-01

Number of tests: 6 Number of wells per test: 5

Storage - pre-aliquoted primers: dark at -20°C

PCR Master Mix: -20°C
 Adhesive PCR seals
 Product Insert
 RT

This Product Description is only valid for Lot No. 70E.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-Cw*18 Lot

The HLA-Cw*18 specificity and interpretation tables have been updated for the HLA-Cw alleles described since the previous *Olerup* SSP® HLA-Cw*18 lot was made (Lot No. X86).

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
4	Exchanged	Exchanged	New primer pair to separate the Cw*1801
			and Cw*0749 alleles.

PRODUCT DESCRIPTION

HLA-Cw*18 SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for identifying the Cw*1801 to Cw*1803 alleles.

PLATE LAYOUT

Each HLA-Cw*18 test consists of 5 PCR reactions in an 8 well cut PCR plate.

Wells 6 to 8 are empty.

1	2	3	4	5	empty	empty	empty

The 8 well PCR plate is marked with 'Cw*18'.

Well No. 1 is marked with the Lot No. '70E'.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

The HLA-Cw*18, Cw*04, Cw*07, Cw*0508 and two Cw*06 alleles will be amplified by the HLA-Cw*18 typing kit. In addition, the B*9537 allele will be amplified by primer mix 5.

UNIQUELY IDENTIFIED ALLELES

All the HLA-Cw*18 alleles, i.e. Cw*1801 to Cw*1803, recognized by the HLA Nomenclature Committee in April 2008¹ will be amplified by the primers in the HLA-Cw*18 SSP kit.

¹HLA-Cw alleles listed on the IMGT/HLA web page 2008-April-08, release 2.21.0, www.ebi.ac.uk/imgt/hla.

RESOLUTION IN HOMO- AND HETEROZYGOTES

The three HLA-Cw*18 alleles can be combined in 6 homozygous and heterozygous combinations. Two of these genotypes do not give rise to unique amplification patterns.

++-++ 1801,1803 = 1803,1803

SPECIFICITY TABLE

HLA-Cw*18 SSP subtyping

Specificities and sizes of the PCR products of the 5 primer mixes used for HLA-Cw*18 SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA- Cw*18 alleles	Other amplified HLA Class I alleles ³
1	425 bp	800 bp	1801-1803	0617, 0707, 0709, 0749
2	560 bp	1070 bp	1801, 1803?	07020101-0733N, 0735-0754
3	220 bp	1070 bp	1802, 1803?	04010101-040105, 0403-0420, 0423- 0432
4	530 bp	1070 bp	1801-1803	
5	165 bp	1070 bp	1803	0508, 0609, B*9537

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-Cw*18 SSP typings.

When the primers in a primer mix can give rise to specific PCR products of more than one length this is indicated if the size difference is 20 base pairs or more. Size differences shorter than 20 base pairs are not given. For high resolution SSP kits the respective length of the specific PCR product(s) of the alleles amplified by these primer mixes are given.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-Cw*18 SSP subtyping.

In the presence of a specific amplification the intensity of the control band often decreases.

³Due to the sharing of sequence motifs between HLA-Cw alleles some non-HLA-Cw*18 alleles will be amplified by primer mixes 1, 2, 3 and 5. In addition, the B*9537 allele will by amplified by primer mix 5.

'?', nucleotide sequence information not available for the primer matching sequence.

INTERPRETATION TABLE					
HLA-Cw*18 SSP subtyping					
Amplification pattern	s of th	e Cw*1	8 allel	es	
			Well		
	1	2	3	4	5
Length of spec.	425	560	220	530	165
PCR product					
Length of int.	800	1070	1070	1070	1070
pos. control ¹					
5'-primer ²	47	956	895	213	412
	^{5'} -Agg ^{3'}	⁵ '-ggT ³ '	^{5'} -ggA ^{3'}	5'-CCC3'	⁵ '-ATA ³ '
3'-primer ³	302	1034	956	459	538
	⁵ '-ggT ³ '	^{5'} -AgC ^{3'}	^{5'} -CAg ^{3'}	^{5'} -ACgA ^{3'}	^{5'} -CCA ^{3'}
Well No.	1	2	3	4	5
HLA-Cw allele					
*1801	1	2		4	
*1802	1		3	4	
*1803	1	?	?	4	5
*04010101-040105, 0403-0420,			3		
0423-0432			3		
*0508, 0609					5
*0617	1				
*070101-0706, 0708, 0710-		2			
0733N, 0735-0748, 0750-0754		_			
*0707, 0709, 0749	1	2			
HLA-Cw allele					
Well No.	1	2	3	4	5
B*9537					5
Well No.	1	2	3	4	5

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-Cw*18 SSP subtyping. 2 The nucleotide position, in the 1st, 4th or 5th exon, matching the specificity-determining 3'-end of

²The nucleotide position, in the 1st, 4^{tn} or 5^{tn} exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the <u>www.ebi.ac.uk/imgt/hla</u> web site. The sequence of the 3 terminal nucleotides of the primer is given.

sequence of the 3 terminal nucleotides of the primer is given.

3The nucleotide position, in the 2nd, 5th or 6th exon, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

CELL LINE VALIDATION SHEET									
	HLA-Cw*18 SSP primer set								
							Nе	II	
				1	1	2	3	4	5
П							_	10	
				.:.	901	200218902	200419003	200847405	200734505
				Z	218	718	119	347	734
				Prod. No.:	20021890	000	8	lõ	00
Н	ILIV	VC call line	+ ,	 Cw*	2	2	2	7	2
1	9001	VC cell line SA	*0702	>W "	Η.	+	-	-	-
2		LK707	*0701	*1505	-	+	-	-	-
3		E4181324	*1202	1303		H	-	-	-
4		GU373	*0304	*0401	<u> </u>	-	+	-	-
5		KAS011	*0602	0.01	-	-	÷	-	-
6	9353		*0304	*0702	1 -	+	-	-	-
7	9020		*0501	1	1 -	1-	-	-	-
8	9007	DEM	*0602	1	-	-	-	-	-
9	9026	YAR	*1203		-	-		-	-
10	9107	LKT3	*0102		-	-	-	-	-
11	9051		*1601		Ŀ	Ŀ	Ŀ	Ŀ	-
12	9052		*0602		<u> </u>	-	-	-	-
13	9067		*0102		<u> </u>	-	-	-	-
14	9071		*0102	*0304	<u> </u>	<u> </u>	-	-	-
15	9075		*0304		Ŀ	-	-	-	-
16	9037	SWEIG007	*0202		<u> </u>	-	-	-	-
17		WILJON	*1203	*0705	Ŀ	-	-	-	-
18 19	9257	32367	*0102 *0701	*0705	Ë	+	-	<u> </u>	-
20		BM16 SLE005	*0701		H	+	Ε.	-	-
21		AMALA	*0304	-	H	H	÷	H	-
22		KOSE	*1203		H	H	H	Ė	
23	9124		*0102	*1502		ļ-	-	-	
24	9035		*1203	1002	-	-	-	-	-
25		IBW9	*0802		i -	-	-	-	-
26		WT49	*0701		T -	+	-	-	-
27	9191		*0704	*1505	۱-	+	-	-	-
28		BEL5GB	*0501	*1601	l -	-	-	-	-
29	9050	MOU	*1601		-	-	-	-	-
30	9021		*1701		L-	Ŀ	Ŀ	Ŀ	-
31	9019	DUCAF	*0501		-	-	Ē	E	-
32	9297		*1701	*1703	-	-	-	-	-
33		MT14B	*0304		Ŀ	-	-	-	-
34	9104		*1203		<u> </u>	-	-	-	-
35		SSTO	*0501	40.15	Ŀ	-	-	-	-
36		KT17	*0303	*0401	-	-	+	-	-
37		HHKB	*0702		Ŀ	+	-	-	-
38	9099		*0303	*0704	Ŀ-	-	-	-	-
39	9315		*0202	*0701	Ë	+	-	-	-
40 41		WHONP199 H0301	*0602	+	H	H	H	÷	-
41		TAB089	*0102		H	H	H	-	-
43		T7526	*0102	*0801	-	-	-	-	-
44	9057		*1203	0001	-	-	-	-	-
45		SHJO	*0602	*17xx	-	-	-	-	-
46		SCHU	*0702		i -	+	-	-	-
47		TUBO	*0704	*1502	-	+	-	-	-
48		TER-ND	*0401		-	Ė	+	-	-
48	9303	TER-ND	*0401	*1601	-	-	+	-	-

HLA-Cw*18 Product Insert Page 6 of 8

101.629-06u – without *Taq* polymerase

Lot No.: **70E** Lot-specific information

CERTIFICATE OF ANALYSIS

Olerup SSP® HLA-Cw*18 SSP

Product number: 101.629-06u – without *Taq* polymerase

Lot number: 70E

Expiry date: 2010-July-01

Number of tests: 6 Number of wells per test: 5

Well specifications:

HLA-Cw*18

Well No.	Production No.
1	2002-189-01
2	2002-189-02
3	2004-190-03
4	2008-474-04
5	2007-345-05

The specificity of each primer solution of the HLA-Cw*18 primer set has been tested against 48 well characterized IHWC cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solution 5 were available. The specificities of the primers in primer solution 5 were tested by separately adding one additional 5'-primer, respectively one additional 3'-primer.

Results: No false positive or false negative amplifications were obtained.

Date of approval: 2009-May-26

Approved by:

Quality Control, Supervisor

HLA-Cw*18 Product Insert Page 7 of 8 101.629-06u – without *Taq* polymerase

Lot No.: **70E** Lot-specific information

Declaration of Conformity

Product name: Olerup SSP® HLA-Cw*18

Product number: 101.629-06u

Lot number: 70E

Intended use: HLA-Cw*18 high resolution histocompatibility testing

Manufacturer: Olerup SSP AB

Hasselstigen 1

SE-133 33 Saltsjöbaden, Sweden

Phone: +46-8-717 88 27 **Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2000, ISO 17025:1999 and ISO 13485:2000, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex III.

The Technical Construction File is maintained at *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

The Authorized Representative located within the Community is: *Olerup* SSP AB.

Saltsjöbaden, Sweden 2009-May-26

Olle Olerup Managing Director HLA-Cw*18 Product Insert Page 8 of 8 101.629-06u – without *Taq* polymerase

Lot No.: **70E** Lot-specific information

Addresses:

Manufacturer:

Olerup SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

Tel: +46-8-717 88 27 **Fax:** +46-8-717 88 18

E-mail: info-ssp@olerup.com *Web page:* http://www.olerup.com

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00 **Fax:** +43-1-710 15 00 10

E-mail: support-at@olerup.com **Web page:** http://www.olerup.com

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1 **Fax:** 610-344-7989

E-mail: info.us@olerup.com

Web page: http://www.olerup.com

For information on Olerup SSP distributors worldwide, contact Olerup GmbH.